Review of NICE Technology Appraisal Guidance No 96, on the use of adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B

Review Decision - October 2007

Following consultation, the majority of comments received have led to the decision to defer the review of existing guidance on the use of adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B until February 2009. At this point we are likely to know the outcome of the appraisals of entecavir and telbivudine for chronic hepatitis B. We will then look again at the evidence base to ascertain the need for a review of the guidance.

The responses from this consultation are below:

• Department of Health
• Royal College of Nursing
• Royal College of Physicians
• NHS Quality Improvement Scotland
• Novartis Pharmaceuticals
• Royal Pharmaceutical Society
• Roche Products
• Gilead Sciences

23 October 2007